Acute Myeloid Leukemia and Myelodysplastic Syndromes | Management of Acute Myeloid Leukemia and Myelodysplastic Syndromes – A Review of the 2022 ASCO Annual Meeting and EHA Congress

Featuring perspectives from Dr Richard Stone, including the following topics:

• Introduction: RATIFY trial in perspective (0:00)
• Treatment with FLT3 inhibitors (7:00)
• Anti-CD47 antibody: Magrolimab (23:04)
• Anti-TIM-3 antibody: Sabatolimab (31:23)
• CAR T-cell therapy for acute myeloid leukemia (34:53)
• Targeted therapy with IDH inhibitors (37:31)
• New myelodysplastic syndromes classification system (41:20)
• Hypomethylating agents/venetoclax (45:11)
• CPX-351 (49:14)
• Other key data sets (50:59)

CME information and select publications